1. Home
  2. ACRV vs BRFH Comparison

ACRV vs BRFH Comparison

Compare ACRV & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • BRFH
  • Stock Information
  • Founded
  • ACRV 2018
  • BRFH 2005
  • Country
  • ACRV United States
  • BRFH United States
  • Employees
  • ACRV N/A
  • BRFH N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • BRFH Packaged Foods
  • Sector
  • ACRV Health Care
  • BRFH Consumer Staples
  • Exchange
  • ACRV Nasdaq
  • BRFH Nasdaq
  • Market Cap
  • ACRV 40.4M
  • BRFH 47.3M
  • IPO Year
  • ACRV 2022
  • BRFH N/A
  • Fundamental
  • Price
  • ACRV $1.34
  • BRFH $3.33
  • Analyst Decision
  • ACRV Buy
  • BRFH Strong Buy
  • Analyst Count
  • ACRV 7
  • BRFH 1
  • Target Price
  • ACRV $17.60
  • BRFH $4.50
  • AVG Volume (30 Days)
  • ACRV 379.9K
  • BRFH 5.5K
  • Earning Date
  • ACRV 08-12-2025
  • BRFH 08-13-2025
  • Dividend Yield
  • ACRV N/A
  • BRFH N/A
  • EPS Growth
  • ACRV N/A
  • BRFH N/A
  • EPS
  • ACRV N/A
  • BRFH N/A
  • Revenue
  • ACRV N/A
  • BRFH $10,818,000.00
  • Revenue This Year
  • ACRV N/A
  • BRFH $42.31
  • Revenue Next Year
  • ACRV N/A
  • BRFH $40.92
  • P/E Ratio
  • ACRV N/A
  • BRFH N/A
  • Revenue Growth
  • ACRV N/A
  • BRFH 22.03
  • 52 Week Low
  • ACRV $1.05
  • BRFH $1.81
  • 52 Week High
  • ACRV $10.16
  • BRFH $4.60
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 55.88
  • BRFH 57.01
  • Support Level
  • ACRV $1.15
  • BRFH $3.18
  • Resistance Level
  • ACRV $1.38
  • BRFH $3.49
  • Average True Range (ATR)
  • ACRV 0.09
  • BRFH 0.30
  • MACD
  • ACRV 0.02
  • BRFH 0.03
  • Stochastic Oscillator
  • ACRV 83.33
  • BRFH 68.35

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About BRFH Barfresh Food Group Inc.

Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.

Share on Social Networks: